nrt ..chart, page-12

re: nrt chart = wrong decision I think we could get $10 per share dividends or more should Phenoxodiol work and get approved.

Look at Gleevec which only treats a small proportion of leukemias. They are already getting $1bn in revenue from this drug. Considering Leukemia is a fairly rare cancer the potential market is massive.

All we need it to start the ball rolling. Either with the trials at RNS in leukemia or Yale for Ovarian. I believe it's currently being tested in prostate cancer patients (oral version). More trials are set to start soon.

I wish we could have weekly updates with these current trials but it's just a matter of time till we see the results.

Cheers,
Munch.